{
  "abstract": "ObjectiveCurrent guidelines recommend different adjuvant treatment strategies for women with endometrioid early-stage endometrial cancer exhibiting a p53-abnormal pattern. We aimed to evaluate recurrence patterns and explore the clinical implications for adjuvant therapy in this population.\n\nMaterials and methodsThis multicenter retrospective study included 86 patients with endometrioid, p53-abnormal, FIGO stage I-II endometrial cancer treated between 2013 and 2023 at six hospitals in the Republic of Korea. Clinicopathologic data were collected through medical record review. Progression-free survival (PFS) was estimated using the Kaplan- Meier method, and prognostic factors were analyzed using Cox proportional hazards regression models.\n\nResultsThe 12-, 24-, and 36-month PFS rates were 91%, 78%, and 76%, respectively. Among the 16 patients who experienced recurrence, 12 (75%) had distant metastases. Adjuvant chemotherapy showed a trend toward improved PFS compared with adjuvant radiation therapy with or without chemotherapy (p=0.10). In multivariable analysis, the p53-overexpression pattern was independently associated with worse PFS compared with the p53-null pattern (HR 8.59, 95% CI 1.61-45.79, p=0.01).\n\nConclusionGiven the poor PFS, the predominance of distant recurrence and the observed trend toward improved PFS with chemotherapy, adjuvant chemotherapy may be considered in women with endometrioid early-stage endometrial cancer exhibiting a p53-abnormal pattern. Further studies are warranted to clarify the prognostic impact of p53 abnormality subtypes.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "name": "S. h. Lee"
    },
    {
      "name": "P. D. Karimah"
    },
    {
      "name": "K. KIM"
    },
    {
      "name": "S. I. Kim"
    },
    {
      "name": "W. Y. Hwang"
    },
    {
      "name": "M. K. Kim"
    },
    {
      "name": "J.-H. Kim"
    },
    {
      "name": "C. H. Choi"
    },
    {
      "name": "Y.-K. Lee"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4yfzy89z22269.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.14.26365577",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365577v1.full",
  "id": "4yfzy89z22269",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365577v1",
  "language": null,
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "obstetrics and gynecology"
    ],
    [
      "openalex",
      "2729|Endometrial and Cervical Cancer Treatments"
    ]
  ],
  "openalex": "W7222878940",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365577v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-14",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4yfzy89z22269.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:01Z",
      "native_id": "10.64898/2026.10.14.26365577",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365577v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:obstetrics and gynecology",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern",
  "title_text": "Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern",
  "type": "preprint",
  "updated_at": "2026-10-30T12:21:01Z",
  "url": "https://research.draconitic.com/paper/4yfzy89z22269",
  "venue": "medRxiv",
  "versions": []
}